

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Ataxia	Potassium channel KCa2.2 (KCNN2); KCNN3; ataxin 2 (ATXN2; SCA2)	<p>Mouse studies suggest positive allosteric modulators (PAMs) of KCNN2 could help treat spinocerebellar ataxia type 2. In SCA2-expressing transgenic mouse models of the condition, Purkinje neurons showed aberrant firing patterns. In cerebellar slices from those mice, NS13001, a PAM of KCNN2 and KCNN3, normalized Purkinje neuron firing patterns. In the mouse model, a PAM optimized for potency against KCNN2 increased motor performance compared with pretreatment baselines. NeuroSearch A/S plans to test NS13001 in other models of cerebellar and/or episodic ataxia.</p> <p>SciBX 5(44); doi:10.1038/scibx.2012.1165 Published online Nov. 8, 2012</p>	Patented by NeuroSearch; available for licensing	<p>Kasumu, A.W. <i>et al. Chem. Biol.</i>; published online Oct. 26, 2012; doi:10.1016/j.chembiol.2012.07.013 Contact: Ilya Bezprozvanny, The University of Texas Southwestern Medical Center, Dallas, Texas e-mail: ilya.bezprozvanny@utsouthwestern.edu Contact: Palle Christophersen, NeuroSearch A/S, Ballerup, Denmark e-mail: pc@neurosearch.com</p>